<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146158</url>
  </required_header>
  <id_info>
    <org_study_id>P070154</org_study_id>
    <nct_id>NCT01146158</nct_id>
  </id_info>
  <brief_title>Axillary Reverse Mapping for Breast Carcinomas</brief_title>
  <acronym>SENTIBRAS</acronym>
  <official_title>Individualisation of the Lymphatic Arm Drainage During Axillary Dissection for Breast Carcinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Distinct arm from breast axillary dissection (AD), or axillary reverse mapping (ARM),
      involves retrieving all breast related nodes while leaving intact the main lymphatic drainage
      chain of the upper limb. This represents a new surgical technique that is the focus of recent
      surgical interest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Distinct arm from breast axillary dissection (AD), or axillary reverse mapping (ARM),
      involves retrieving all breast related nodes while leaving intact the main lymphatic drainage
      chain of the upper limb. This represents a new surgical technique that is the focus of recent
      surgical interest. The assumption is that the sentinel node (SN) of the upper limb is
      different from the SN of the breast and that it is uninvolved after metastatic involvement of
      the axillary nodes in relation to the breast. During the ARM procedure, it is necessary to
      use an injection of a lymphatic tracer into the upper limb in order to visualize the
      lymphatic arm drainage.The ultimate goal for ARM procedure is to reduce the rate of
      lymphedema in N+ patients requiring an AD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of the principal objectives is qualified as finding one or more radioactive node in zone D</measure>
    <time_frame>1 day</time_frame>
    <description>Zone D is the area lateral to the lateral thoracic vein and extending from the second intercostobrachial nerve to the axillary vein.
If all radioactive nodes are found below the second intercostobrachial nerve (Zone C, A) or medial to the lateral thoracic vein (Zone A, B) this qualifies a failure of the main objective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of metastatic or micro-metastatic disease within the &quot;SENTIBRAS &quot; node</measure>
    <time_frame>15 days</time_frame>
    <description>Evaluate the incidence of metastatic or micro-metastatic disease within</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between clinical and histological results</measure>
    <time_frame>15 days</time_frame>
    <description>Evaluate the correlation between clinical and histological results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the morbidity associated with Axillary Dissection.</measure>
    <time_frame>1 year, 2 years and 5 years</time_frame>
    <description>Evaluate the morbidity associated with Axillary Dissection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Axillary Dissection</condition>
  <arm_group>
    <arm_group_label>surgery Axillary dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgery Axillary dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary dissection for breast carcinomas</intervention_name>
    <description>surgery Axillary dissection</description>
    <arm_group_label>surgery Axillary dissection</arm_group_label>
    <other_name>surgery Axillary dissection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for formal Axillary Dissection (AD)

          -  N0 patient with a large tumor: T3

          -  N1 patient

          -  N2 patient with axillary imaging showing limited node involvement(1-4N+).

          -  Secondary AD after a positive sentinel node ( pN1, pN1(mi))

          -  AD after préopérative chemotherapy in a patient initially N+.

          -  Age between 18 and 70

          -  Signature of the consent form.

          -  Patients beneficiary of the Social Security

        Exclusion Criteria:

          -  N0 patient with an indication of Sentinel Node biopsy

          -  N2 patient with axillary imaging showing suspected node involvement &gt;4N+.

          -  N3 patient

          -  Age over 70

          -  Pregnancy

          -  Blue dye allergy

          -  Mentally deficient patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude NOS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital European Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Nos C, Lesieur B, Clough KB, Lecuru F. Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol. 2007 Sep;14(9):2490-6. Epub 2007 Jun 5.</citation>
    <PMID>17549570</PMID>
  </reference>
  <reference>
    <citation>Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, Lecuru F. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol. 2008 Sep;15(9):2550-5. doi: 10.1245/s10434-008-0030-z. Epub 2008 Jul 11.</citation>
    <PMID>18618185</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axillary dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

